Your AI-Trained Oncology Knowledge Connection!

Prophylactic Tocilizumab to Prevent Cytokine Release Syndrome With Teclistamab Administration : Episode 5

Study Conclusions and Its Implications

January 8, 2024

By Sagar Lonial, MD, FACP
Ellen Marin, PA-C

Opinion

Video

Ellen Marin, PA-C, presents the study conclusions and discusses its implications on managing CRS associated with teclistamab with Dr. Lonial.

EP: 1.Overview of Relapsed or Refractory Multiple Myeloma (RRMM)

EP: 2.Overview of Cytokine Release Syndrome (CRS) and Its Management

EP: 3.Background Information and Study Method

EP: 4.Patient Demographics and Study Results

EP: 5.Study Conclusions and Its Implications

EP: 6.Study Impact and Key Takeaways

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Recent Videos

Elucidating nonresponses to bispecific T-cell engagers may be an important research consideration in the multiple myeloma field.

Fixed treatment durations with bispecific antibodies followed by observation may help in mitigating infection-related AEs, according to Shebli Atrash, MD.

Shebli Atrash, MD, stated that MRD should be considered carefully as an end point, given potential recurrence despite MRD negativity.

OncNursingNews.com

TargetedOnc.com

Terms and Conditions

Do Not Sell My Personal Information

Contact Info

2 Commerce Drive
Cranbury, NJ 08512

© 2025 MJH Life Sciences

All rights reserved.